Literature DB >> 21227420

Socioeconomic and ethnic differences in use of lipid-lowering drugs after deregulation of simvastatin in the UK: the Whitehall II prospective cohort study.

Ian Forde1, Tarani Chandola, Rosalind Raine, Michael G Marmot, Mika Kivimaki.   

Abstract

BACKGROUND: We examined socioeconomic and ethnic differences in use of lipid-lowering drugs after deregulation of simvastatin in the UK for adults with moderate or high risk of coronary heart disease.
METHODS: 3631 participants in the Whitehall II cohort study (mean age 62.7 years, 91% white) were informed of their risk of coronary heart disease, based on Framingham score, before deregulation (2002-2004). The use of prescribed lipid-lowering drugs and use of over-the-counter simvastatin were analysed as outcome variables, after deregulation (2005-2007).
RESULTS: 2451 participants were at high risk and 1180 at moderate risk. 20% moderate-risk and 44% high-risk participants reported using prescribed lipid-lowering drugs although no over-the-counter simvastatin was used. Prescribing rates did not differ between employment grades (an index of socioeconomic position), but was higher among South Asian high-risk compared with White high-risk participants (odds ratio 1.64, 95% CI 1.21-2.23). Of the high-risk participants, 44% recalled their increased coronary heart disease risk. South Asian high-risk participants were less likely to recall than White high-risk participants (odds ratio 0.65, 95% CI 0.46-0.93). Furthermore, high risk participants with middle (odds ratio 0.74, 95% CI 0.61-0.89) and low (odds ratio 0.52, 95% CI 0.37-0.74) employment grades were less likely to recall than those with high grades.
CONCLUSION: Socioeconomic and ethnic differences in reported use of lipid-lowering drugs were small, but the use of these drugs in general was much lower than recommended and the participants did not utilise over-the-counter statins. Ethnic minorities and lower socioeconomic position groups were less likely to be aware of their increased coronary risk.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21227420      PMCID: PMC3249398          DOI: 10.1016/j.atherosclerosis.2010.12.012

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  20 in total

1.  Socioeconomic differences in attitudes and beliefs about healthy lifestyles.

Authors:  J Wardle; A Steptoe
Journal:  J Epidemiol Community Health       Date:  2003-06       Impact factor: 3.710

2.  OTC statins: a bad decision for public health.

Authors: 
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

Review 3.  Socio-economic status of the patient and doctor-patient communication: does it make a difference?

Authors:  S Willems; S De Maesschalck; M Deveugele; A Derese; J De Maeseneer
Journal:  Patient Educ Couns       Date:  2005-02

4.  Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'.

Authors:  M Ashworth; D Lloyd; R S Smith; A Wagner; G Rowlands
Journal:  J Public Health (Oxf)       Date:  2006-10-27       Impact factor: 2.341

Review 5.  Socioeconomic factors and cardiovascular disease: a review of the literature.

Authors:  G A Kaplan; J E Keil
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

6.  Non-response to baseline, non-response to follow-up and mortality in the Whitehall II cohort.

Authors:  Jane E Ferrie; Mika Kivimäki; Archana Singh-Manoux; Alison Shortt; Pekka Martikainen; Jenny Head; Michael Marmot; David Gimeno; Roberto De Vogli; Marko Elovainio; Martin J Shipley
Journal:  Int J Epidemiol       Date:  2009-03-05       Impact factor: 7.196

7.  Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?

Authors:  F D A Reid; D G Cook; P H Whincup
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

8.  Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: use of individual and combination treatment.

Authors:  S DeWilde; I M Carey; N Richards; P H Whincup; D G Cook
Journal:  Heart       Date:  2007-05-31       Impact factor: 5.994

9.  Cohort Profile: the Whitehall II study.

Authors:  Michael Marmot; Eric Brunner
Journal:  Int J Epidemiol       Date:  2004-12-02       Impact factor: 7.196

10.  Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework.

Authors:  Sheena E Ramsay; Richard W Morris; Olia Papacosta; Lucy T Lennon; Mary C Thomas; Peter H Whincup
Journal:  J Public Health (Oxf)       Date:  2005-09-14       Impact factor: 2.341

View more
  6 in total

1.  Subclinical carotid atherosclerosis and neurocognitive function in an urban population.

Authors:  Carrington R Wendell; Shari R Waldstein; Michele K Evans; Alan B Zonderman
Journal:  Atherosclerosis       Date:  2016-04-08       Impact factor: 5.162

2.  Socio-Economic Differences in the Association between Self-Reported and Clinically Present Diabetes and Hypertension: Secondary Analysis of a Population-Based Cross-Sectional Study.

Authors:  Gerald Tompkins; Lynne F Forrest; Jean Adams
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

3.  Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study.

Authors:  Helle Wallach-Kildemoes; Finn Diderichsen; Allan Krasnik; Theis Lange; Morten Andersen
Journal:  BMC Public Health       Date:  2012-08-04       Impact factor: 3.295

4.  Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study.

Authors:  Jianhua Wu; Shihua Zhu; Guiqing Lily Yao; Mohammed A Mohammed; Tom Marshall
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

5.  Statin prescription in patients with chronic obstructive pulmonary disease and risk of exacerbations: a retrospective cohort study in the Clinical Practice Research Datalink.

Authors:  Margaret C Smith; Helen Frances Ashdown; James Peter Sheppard; Christopher C Butler; Clare Bankhead
Journal:  BMJ Open       Date:  2021-12-07       Impact factor: 2.692

6.  Cross-sectional analysis of educational inequalities in primary prevention statin use in UK Biobank.

Authors:  Neil M Davies; Laura D Howe; Alice Rose Carter; Dipender Gill; George Davey Smith; Amy E Taylor
Journal:  Heart       Date:  2021-07-27       Impact factor: 5.994

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.